shRNA silencing or a recombinant matriptase inhibitor blocked Namalwa and Raji cells and patient CLL cells in matrigel invasion (Figure 2) . The results indicate that matriptase may contribute to the invasiveness of these B-cell-derived cancer cells, either directly by degrading matrix proteins or indirectly by activating growth factors or other unknown mechanisms. Our findings suggest that matriptase inhibition may be tested as a new therapeutic strategy to prevent CLL cell invasion and metastasis.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia-impact on minimal residual disease detection Leukemia (2013) 27, 1194-1196; doi:10.1038/leu.2012.291
Wilms' tumor gene 1 (WT1) is located on chromosome 11p13. As a zinc finger transcription factor, WT1 regulates expression of many target genes involved in regulation of cell cycle, proliferation, differentiation and apoptosis. 1, 2 Overexpression of WT1 was found in majority of acute leukemias and other hematological malignancies. WT1 has, therefore, been intensively studied as a potential prognostic factor, marker for minimal residual disease (MRD) and target for immunotherapy (summarized in references 1, [3] [4] [5] ).
In this report, we focus on the role of WT1 as a marker for monitoring of malignant cells in patients with childhood acute myeloid leukemia (AML). Many important studies proved the usefulness of WT1 for this purpose, showing that this gene provides a promising tool for residual disease detection. In general, these studies were based on the analysis of bone marrow (BM) samples, [6] [7] [8] while only minority used peripheral blood (PB) as a source of leukemic cells. 9, 10 Considering the fact, that the percentage of blasts can differ between BM and PB, one could assume that the choice of material for WT1 detection may influence the subsequent analysis. Nevertheless, no consensus has been made so far.
Accepted article preview online 10 October 2012; advance online publication, 13 November 2012 To investigate whether both BM and PB provide similar information on leukemia burden in childhood AML measured by WT1 expression, we determined the diagnostic level of WT1 in 90 children with AML treated in the Czech Pediatric Hematology (CPH) centers (Table 1) . Following ethical committee approval and informed consent, paired samples of BM and PB were processed as described earlier 11 and the resulting cDNA was used for quantification of WT1 and ABL control gene by the quantitative PCR assay of our own design. 12 To define the physiological level of WT1, we also analyzed 24 samples of healthy BM and PB donors.
Physiological expression of WT1 in unsorted BM and PB samples was 28 and 1.4 WT1/ABL Â 10 4 NCN (range 8-115 and 0.2-13.2), respectively. In leukemic patients, the level of WT1 in BM was 0.2 log higher when compared with PB (median 2587 (range 0-57065) WT1/ABL Â 10 4 NCN for BM and 1640 (range 0-16517) WT1/ ABL Â 10 4 NCN for PB; P ¼ 0.02; Figure 1a ). WT1 overexpression (defined as 41.5-fold higher than maximum of physiological level) was found in 76% of BM and 80% of PB samples. The difference in WT1 expression between patients' samples and healthy controls was 3.1 logs for PB in contrast to only 2.0 logs for BM (Figure 1b) .
Comparison of paired BM and PB levels of WT1 revealed an excellent correlation between these values with the correlation coefficient of 0.89 (Po0.0001; Figure 1c ). However, there was no relation between WT1 levels in PB or BM and the percentage of blasts.
According to French-American-British (FAB) classification, M3 subtype of AML was associated with the highest WT1 expression, while patients with M5 AML had the lowest WT1 level (Po0.0001 for both BM and PB; Figure 1d ). Standard risk cases expressed WT1 on higher level compared with high risk group (Po0.0001 for both BM and PB). We could not prove any relation of WT1 level to age, sex or d15 treatment response. Neither did the expression of WT1 correlate with survival characteristics of our cohort of childhood AML; patients with high and low initial level of WT1 had the same relapse-free survival probability (Figure 1e ). In summary, we found an excellent correlation of WT1 expression in paired BM and PB samples. However, in contrast to studies mostly on adult AML, we could not confirm the prognostic significance of WT1 expression at diagnosis of pediatric AML. Comparison of WT1 levels in healthy controls and leukemia samples revealed a wider distance between physiological and malignant expression of WT1 in PB. This observation makes PB superior to BM for monitoring of MRD by WT1 expression.
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study Leukemia (2013) 27, 1196-1201; doi:10.1038/leu.2012.292
Chronic graft-versus-host disease (CGVHD) is one of the most debilitating complications post hematopoietic cell transplant (HCT). Several studies have evaluated the factors affecting survival in CGVHD, [1] [2] [3] [4] [5] [6] [7] [8] most utilizing the older definition of CGVHD, where patients with any symptoms of GVHD (acute or chronic) may be classified as CGVHD if found symptomatic beyond day 100 post HCT. However, the new National institutes of health (NIH) consensus guidelines have redefined the criteria for CGVHD diagnosis and staging 9 based on the actual symptoms at presentation, and excludes the patients with persistent, recurrent or late acute graft-versus-host disease (AGVHD) who were previously considered to have CGVHD. The CGVHD consortium follows a large multicenter prospectively enrolled cohort of CGVHD patients utilizing NIH consensus guidelines for assessments. 10 Several reports from this consortium have identified factors affecting survival, including global severity, thrombocytopenia, karnofsky performance score and overlap syndrome. 11, 12 Prior AGVHD has been associated with a higher mortality in patients who develop CGVHD, 1, 3 indicating that these patients may be more debilitated and hence suffer worse outcome. However, the clinical and prognostic importance of prior AGVHD on subsequent CGVHD in the current era, using NIH diagnostic and staging criteria, is unknown. We evaluated the significance of prior AGVHD on CGVHD presentation, overall response and survival in a contemporary cohort of CGVHD patients prospectively enrolled by the CGVHD consortium. Cases enrolled in the consortium could be incident (enrollment o3 months after diagnosis) or prevalent (enrollment X3 months after diagnosis). 10 Detailed CGVHD assessments were performed reflecting the recommendations of the NIH consensus conference, 9, 13 and are published in the cohort study rationale and design summary. 10 Prior AGVHD was considered to be present if maximum grade I À IV was reported. Comparisons were performed between two groups: Prior AGVHD and no prior AGVHD. Statistical comparisons between groups were made with the two-sample t-test for continuous variables, and w 2 -test for categorical variables. Spearman correlation coefficient (r,) and simple k-statistics were used to describe rank correlation and agreement between AGVHD Accepted article preview online 10 october 2012; advance online publication, 26 October 2012
